Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older.

Thomsen FB, Bandak M, Thomsen MF, Lauritsen J, Christensen IJ, Daugaard G.

Cancer. 2014 Jan 1;120(1):43-51. doi: 10.1002/cncr.28374.

3.

Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.

Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, Matveev V, Zakharova T, Garin A, Tjulandin S.

Urology. 2011 Sep;78(3):620-5. doi: 10.1016/j.urology.2011.05.005.

PMID:
21764427
4.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group..

Br J Cancer. 2005 Nov 28;93(11):1209-14.

5.

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ.

J Clin Oncol. 2007 Jan 20;25(3):247-56.

PMID:
17235042
6.

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C; German Testicular Cancer Study Group..

J Clin Oncol. 2003 Nov 15;21(22):4083-91.

PMID:
14568987
7.

Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.

Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N, Trump D, Loehrer PJ Sr.

Cancer. 2003 Apr 15;97(8):1869-75.

8.

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.

de Wit R, Skoneczna I, Daugaard G, De Santis M, Garin A, Aass N, Witjes AJ, Albers P, White JD, Germa-Lluch JR, Marreaud S, Collette L.

J Clin Oncol. 2012 Mar 10;30(8):792-9. doi: 10.1200/JCO.2011.37.0171.

9.

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).

Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Ståhl E, Cohn-Cedermark G.

Acta Oncol. 2012 Feb;51(2):168-76. doi: 10.3109/0284186X.2011.641507.

PMID:
22175254
11.

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group..

J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Erratum in: J Clin Oncol. 2010 Mar 10;28(8):1439. Dosage error in article text.

PMID:
18458040
12.

Treatment outcome and cost-effectiveness analysis of two chemotherapeutic regimens (BEP vs. VIP) for poor-prognosis metastatic germ cell tumors.

Attili VS, Chandra RC, Anupama G, Loknath D, Bapsy PP, Dadhich HK, Babu GK.

J Cancer Res Ther. 2007 Jul-Sep;3(3):150-2.

13.

Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients.

Kawai K, Ando S, Hinotsu S, Oikawa T, Sekido N, Miyanaga N, Shimazui T, Akaza H.

Jpn J Clin Oncol. 2006 Jul;36(7):425-31.

14.

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.

Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC.

J Natl Cancer Inst. 2010 Aug 18;102(16):1253-62. doi: 10.1093/jnci/djq245.

15.

Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.

Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J, Parashar D, Armstrong G, Mazhar D, Williams MV.

Br J Cancer. 2011 Sep 6;105(6):766-72. doi: 10.1038/bjc.2011.309.

16.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP..

J Clin Oncol. 2008 Jan 20;26(3):421-7. doi: 10.1200/JCO.2007.13.8461.

PMID:
18202419
17.

Management of good risk germ-cell tumours.

Troost MM, Sternberg CN, de Wit R.

BJU Int. 2009 Nov;104(9 Pt B):1387-91. doi: 10.1111/j.1464-410X.2009.08864.x. Review.

18.

Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.

Chen CA, Lin H, Weng CS, Wen KC, Lu CH, Chou HH, Huang YF, Kang CY, Ho CM, Yu MH, Chou CY.

Eur J Cancer. 2014 Dec;50(18):3161-7.

PMID:
25459394
19.

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.

Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ.

Br J Cancer. 2002 May 20;86(10):1555-60.

Items per page

Supplemental Content

Support Center